Tenaya Therapeutics (TNYA) said Monday that preclinical data for TN-201, its gene therapy candidate for myosin-binding protein C3-associated hypertrophic cardiomyopathy, showed improved heart function.
Published preclinical data also showed extended survival and lower cardiac biomarkers associated with fibrosis and heart failure, the company said.
A mouse surrogate of TN-201 was tested against vehicle in a model that mimics severe disease in humans, Tenaya said.
The company said the results, which were dose-dependent and lasted 20 months after treatment, support its clinical development plan for TN-201. Tenaya is conducting a phase 1b/2 clinical trial to assess TN-201 as a potential treatment for myosin-binding protein C3-associated hypertrophic cardiomyopathy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。